Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $37 to $56.
June 12, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Disc Medicine and raises the price target from $37 to $56.
Morgan Stanley's decision to maintain an Overweight rating on Disc Medicine and raise the price target from $37 to $56 indicates a positive outlook for the stock. This could lead to an increase in investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100